Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
FRACTYL HEALTH, INC. GUTS

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 11, 2026 8-K 2 signals fired
Other
Reverse Stock Split Effected Nasdaq Minimum Bid Price Delisting Notice
Aug 10, 2026 10-Q 31 signals fired · top 15
Other
Warrant Valued Black Scholes Net Loss Reported Revenue Increase Attribution Disclosure Financing Activities Cash Flow Disclosure Fair Value Hierarchy Reconciliation Disclosed Shares Outstanding Disclosure Personnel Cost Decrease Disclosure Other Income Expense Disclosure Cash Flow Statement Investing Activities Lease Rou Incremental Borrowing Rate Disclosure Equity Plan Share Reserve Disclosure Patient Retention High Gene Therapy Aav
Core
Clinical Trial Result Lead Asset Progress
Aug 10, 2026 8-K 11 signals fired
Other
Sga Expense Comparison Disclosed Adjusted Ebitda Period Comparison Net Loss Reported Gene Therapy Aav Patient Retention High Fast Track Granted Burn Rate Controlled Administrative Efficiency Interim Data Positive
Core
Clinical Trial Result Clinical Hold
Jul 15, 2026 8-K 10 signals fired
Core
Clinical Trial Result Secondary Endpoint Mentioned Combination Therapy Mentioned Clinical Hold
Other
Board Committee Member Listing Patient Retention High Fda Breakthrough Device Designation Interim Data Positive Fda Aligned Orphan Status Granted
Jun 11, 2026 8-K 1 signal fired
Other
Quorum Presence Disclosed
Jun 4, 2026 8-K 7 signals fired
Core
Clinical Trial Result Secondary Endpoint Mentioned
Other
Patient Retention High Interim Data Positive Ce Mark Received Fda Breakthrough Device Designation Enrollment Ahead Of Schedule
May 12, 2026 10-Q 35 signals fired · top 15
Other
Warrant Valued Black Scholes Ipo Or Capital Raising Completion Net Loss Reported Segment Aggregation Disclosure Fair Value Hierarchy Reconciliation Disclosed Capital Raising Uncertainty Disclosed Financing Activities Cash Flow Disclosure Shares Outstanding Disclosure Form S3 Shelf Registration Disclosure Nasdaq Minimum Bid Price Delisting Notice Cash Flow Statement Investing Activities Other Income Expense Disclosure Equity Plan Share Reserve Disclosure Institutional Investment
Core
Clinical Trial Result
May 12, 2026 8-K 20 signals fired · top 15
Other
Adjusted Ebitda Period Comparison Sga Expense Comparison Disclosed Gene Therapy Aav Administrative Efficiency Burn Rate Controlled Net Loss Reported Protocol Amended Personnel Cost Decrease Disclosure Interim Data Positive Enrollment Ahead Of Schedule
Core
Indication Expansion Clinical Trial Result Lead Asset Progress
Business Services
Demand Softening
Biotech Risk
Clinical Hold Active
May 11, 2026 8-K 17 signals fired · top 15
Core
Secondary Endpoint Mentioned Clinical Trial Result Lead Asset Progress Indication Expansion Clinical Hold
Other
Gene Therapy Aav Interim Data Positive Kol Endorsement Enrollment Ahead Of Schedule Protocol Amended Publication Positive Fda Aligned Safety Differentiated
Biotech v3
Ind Submission Planned
Biotech Risk
Clinical Hold Active
Mar 24, 2026 10-K 6 signals fired
Other
Ltip Plan Title Citation Transfer And Demand Rights Limitations Share Withholding Tax Settlement Nyse Listing Disclosure Performance Unit Award Establishment Nonqualified Stock Option Exercise Or Grant
Mar 24, 2026 8-K 17 signals fired · top 15
Other
Sga Expense Comparison Disclosed Adjusted Ebitda Period Comparison Net Loss Reported Interim Data Positive Gene Therapy Aav Fda Breakthrough Device Designation Fda Aligned Patient Retention High Protocol Amended
Core
Lead Asset Progress Indication Expansion Clinical Trial Result Clinical Hold
Biotech Risk
Trial Endpoint Missed Clinical Hold Active